Molecular Partners develops its proprietary DARPin therapeutics through a systematic, modular discovery and engineering platform centered on high-throughput screening and recombinant protein expression. The process begins by utilizing vast, pre-defined libraries of engineered ankyrin repeat domains that contain randomized surface residues capable of binding diverse molecular targets. Using ribosome display and rapid in vitro selection techniques, researchers identify candidate DARPins with high affinity against specific disease targets. These modular building blocks are then genetically linked to create multi-specific or multivalent constructs, optimized for half-life extension, and scaled up cost-effectively using microbial fermentation before advancing through preclinical testing and clinical trials.